An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0
|
作者：
Johnston, P. B.
Lewis, L. T.
Rogerio, J. W.
机构：
[1] Mayo Clin Rochester, Rochester, MN USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps299
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS299
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Graham, Anne
    Ramchandren, Radhakrishnan
    BLOOD, 2011, 118 (21) : 1169 - 1169
  • [2] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Radhakrishnan
    BLOOD, 2012, 120 (21)
  • [3] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Rogerio, Jaqueline Willemann
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Rod
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
    Younes, Anas
    Oki, Yasuhiro
    Bociek, R. Gregory
    Kuruvilla, John
    Fanale, Michelle
    Neelapu, Sattva
    Copeland, Amanda
    Buglio, Daniela
    Galal, Ahmed
    Besterman, Jeffrey
    Li, Zuomei
    Drouin, Michel
    Patterson, Tracy
    Ward, M. Renee
    Paulus, Jessica K.
    Ji, Yuan
    Medeiros, L. Jeffrey
    Martell, Robert E.
    LANCET ONCOLOGY, 2011, 12 (13): : 1222 - 1228
  • [5] A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
    Song, Yuqin
    Wu, Jianqiu
    Chen, Xinchuan
    Lin, Tongyu
    Cao, Junning
    Liu, Yanyan
    Zhao, Yaozhong
    Jin, Jie
    Huang, Haiwen
    Hu, Jianda
    Luo, Jun
    Zhang, Liling
    Xue, Hongwei
    Zhang, Qingyuan
    Wang, Weiwei
    Chen, Chunxia
    Feng, Jifeng
    Zhu, Jun
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7363 - 7369
  • [6] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] mTOR inhibition for relapsed or refractory Hodgkin lymphoma: Promising single agent activity with Everolimus (RAD001)
    Johnston, Patrick B.
    Ansell, Steven M.
    Colgan, Josph P.
    Habermann, Thomas M.
    Inwards, David J.
    Micallef, Lvana N. M.
    Porrata, Luis F.
    Reeder, Craig B.
    Roy, Vivek
    LaPlant, Betsy R.
    Wilzig, Thomas E.
    BLOOD, 2007, 110 (11) : 753A - 753A
  • [8] Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    BLOOD, 2009, 114 (22) : 1481 - 1481
  • [9] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [10] Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL).
    Ogura, Michinori
    Uchida, Toshiki
    Maruyama, Dai
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    Tobinai, Kensei
    BLOOD, 2009, 114 (22) : 682 - 683
12345